Meet Our Scientific Advisory Board

Paola Neri, MD, PhD

University of Calgary, Arnie Charbonneau Cancer Institute

Dr. Paola Neri, MD, PhD is an Associate Professor of Medicine, attending physician in the Hematology division at University of Calgary and member of the Arnie Charbonneau Cancer Institute. Since January 2019 she is the Scientific Director of the Precision Oncology Hub, Translational Research Laboratory, at the Tom Baker Cancer Centre (TBCC) in Calgary.

Dr. Neri received her medical degree at Magna Græcia University, Catanzaro, Italy in 2000. She completed her specialty in Medical Oncology at Magna Græcia University, Catanzaro, Italy in 2005 and received a PhD in Molecular Oncology and Experimental Immunology in 2011.  From 2003-2006 she was Research Associate at Dana-Farber Cancer Institute, Harvard Medical School, Boston, USA under the mentorship of Dr. Kenneth Anderson. In June 2008, she joined the University of Calgary.

The main focus of her research is the study of multiple myeloma (MM) with a particular interest in drug development and genomic studies with the goal of discovering novel therapeutic targets for this incurable disease. As such she has investigated the genome signature associated with MM cell response or resistance to anti-MM agents to identify druggable therapeutic targets in MM and new biomarkers of response to novel agents.

Dr. Neri is well published in the field and received national and international grants from several agencies including International Myeloma Society, Leukemia and Lymphoma Society, Multiple Myeloma Research Foundation and Canadian Institute of Health Research (CIHR).

In 2019 she received the Engineered Air Chair (research funds) in Cancer Research from the University of Calgary. In 2021 she was selected by the International Myeloma Society to receive the Ken Anderson Young Investigator Award for her impressive translational work in multiple myeloma.

She is currently member of the American Society of Hematology, co-chair of Charbonneau Research & Innovation Committee in Calgary and member of Blood Editorial Board, very active both in preclinical and clinical trial research in Myeloma.